Elektrofi
Boston
About Elektrofi
Elektrofi develops biologic therapies through its hyper concentration microparticle platform technology, Hypercon. The company focuses on reengineering medicine delivery to support partners and patients with smarter administration methods. Elektrofi collaborates with other biopharma companies to develop new generation medicines that can be delivered subcutaneously.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $154.1M
- Funding stage: M&A
- Last round: Series C (Aug 2024)
- Website: elektrofi.com
- Phone: 866-610-2683
Industries & Categories
Alternative Medicine, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/elektrofi-89818 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.